T. Rowe Price Investment Management, Inc. Vaxcyte, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $151 Billion
- Q1 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 2,702,691 shares of PCVX stock, worth $92.8 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
2,702,691
Previous 2,860,717
5.52%
Holding current value
$92.8 Million
Previous $234 Million
56.42%
% of portfolio
0.07%
Previous 0.14%
Shares
10 transactions
Others Institutions Holding PCVX
# of Institutions
345Shares Held
136MCall Options Held
348KPut Options Held
250K-
Ra Capital Management, L.P. Boston, MA12.2MShares$418 Million9.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$413 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X011.8MShares$404 Million0.25% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$341 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA6.42MShares$220 Million0.05% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.04B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...